Reducing time to differentiated service delivery for newly diagnosed people living with HIV in Kigali, Rwanda: study protocol for a pilot, unblinded, randomised controlled study

Jonathan Ross, Gad Murenzi, Sarah Hill, Eric Remera, Charles Ingabire, Francine Umwiza, Athanase Munyaneza, Benjamin Muhoza, Dominique Savio Habimana, Placidie Mugwaneza, Chenshu Zhang, Marcel Yotebieng, Kathryn Anastos, Jonathan Ross, Gad Murenzi, Sarah Hill, Eric Remera, Charles Ingabire, Francine Umwiza, Athanase Munyaneza, Benjamin Muhoza, Dominique Savio Habimana, Placidie Mugwaneza, Chenshu Zhang, Marcel Yotebieng, Kathryn Anastos

Abstract

Introduction: Current HIV guidelines recommend differentiated service delivery (DSD) models that allow for fewer health centre visits for clinically stable people living with HIV (PLHIV). Newly diagnosed PLHIV may require more intensive care early in their treatment course, yet frequent appointments can be burdensome to patients and health systems. Determining the optimal parameters for defining clinical stability and transitioning to less frequent appointments could decrease patient burden and health system costs. The objectives of this pilot study are to explore the feasibility and acceptability of (1) reducing the time to DSD from 12 to 6 months after antiretroviral therapy (ART) initiation,and (2) reducing the number of suppressed viral loads required to enter DSD from two to one.

Methods and analyses: The present study is a pilot, unblinded trial taking place in three health facilities in Kigali, Rwanda. Current Rwandan guidelines require PLHIV to be on ART for ≥12 months with two consecutive suppressed viral loads in order to transition to less frequent appointments. We will randomise 90 participants to one of three arms: entry into DSD at 6 months after one suppressed viral load (n=30), entry into DSD at 6 months after two suppressed viral loads (n=30) or current standard of care (n=30). We will measure feasibility and acceptability of this intervention; clinical outcomes include viral suppression at 12 months (primary outcome) and appointment attendance (secondary outcome).

Ethics and dissemination: This clinical trial was approved by the institutional review board of Albert Einstein College of Medicine and by the Rwanda National Ethics Committee. Findings will be disseminated through conferences and peer-reviewed publications, as well as meetings with stakeholders.

Trial registration number: NCT04567693.

Keywords: HIV & AIDS; clinical trials; international health services.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Joint United Nations Programme on HIV/AIDS . 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland, 2014.
    1. World Health Organization, Department of HIV/AIDS . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016: recommendations for a public health approach. 2nd edn. Geneva, Switzerland: World Health Organization, 2016.
    1. Rwanda summary sheet, population-based HIV health impact assessment [online]. Available: [Accessed 6 Oct 2020].
    1. Phiri K, McBride K, Siwale Z, et al. . Provider experiences with three- and six-month antiretroviral therapy dispensing for stable clients in Zambia. AIDS Care 2021;33:1–7. 10.1080/09540121.2020.1755010
    1. Eshun-Wilson I, Mukumbwa-Mwenechanya M, Kim H-Y, et al. . Differentiated care preferences of stable patients on antiretroviral therapy in Zambia: a discrete choice experiment. J Acquir Immune Defic Syndr 2019;81:540–6. 10.1097/QAI.0000000000002070
    1. Long L, Kuchukhidze S, Pascoe S, et al. . Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic review. J Int AIDS Soc 2020;23:e25640. 10.1002/jia2.25640
    1. Fatti G, Ngorima-Mabhena N, Mothibi E, et al. . Outcomes of three- versus sexi-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART refill groups: a cluster-randomized trial in Zimbabwe. J Acquir Immune Defic Syndr 2020;84:162–72. 10.1097/QAI.0000000000002333
    1. Tukei BB, Fatti G, Tiam A, et al. . Twelve-month outcomes of community-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in lesotho: a cluster-randomized noniferiority trial. J Acquir Immune Defic Syndr 2020;85:280–91. 10.1097/QAI.0000000000002439
    1. Differentiated service delivery. Available: [Accessed 5 Mar 2021].
    1. U.S. Department of State . PEPFAR technical guidance in context of COVID-19 pandemic, 24 February 2021. Available: [Accessed 5 Mar 2021].
    1. Prust ML, Banda CK, Nyirenda R, et al. . Multi-month prescriptions, fast-track refills, and community ART groups: results from a process evaluation in Malawi on using differentiated models of care to achieve national HIV treatment goals. J Int AIDS Soc 2017;20:21650. 10.7448/IAS.20.5.21650
    1. Wringe A, Cawley C, Szumilin E, et al. . Retention in care among clinically stable antiretroviral therapy patients following a six-monthly clinical consultation schedule: findings from a cohort study in rural Malawi. J Int AIDS Soc 2018;21:e25207. 10.1002/jia2.25207
    1. PEPFAR Burundi country operational plan (COP) 2017 strategic direction summary April 29, 2017. Available: [Accessed 23 Oct 2020].
    1. Rwanda Biomedical Center . National guidelines for prevention and management of HIV and STIs. Kigali, Rwanda, 2016.
    1. Ingabire C, Umwiza F, Gasana J. “It’s a big problem to take that pill before you feel ready”: ART initiation challenges under treat all in rwanda. oral presentation, international conference on AIDS and STDs in Africa. Kigali, Rwanda, 2019.
    1. Ross J, Ribakare M, Remera E, et al. . High levels of viral load monitoring and viral suppression under Treat All in Rwanda - a cross-sectional study. J Int AIDS Soc 2020;23:e25543. 10.1002/jia2.25543
    1. Rwanda Biomedical Center . Rwanda HIV and AIDS national strategic plan 2013-2018; extension 2018-2020. Rwanda: Kigail.
    1. Lannes L. Improving health worker performance: the patient-perspective from a PBF program in Rwanda. Soc Sci Med 2015;138:1–11. 10.1016/j.socscimed.2015.05.033
    1. Parcesepe A, Tymejczyk O, Remien R, et al. . HIV-related stigma, social support, and psychological distress among individuals initiating art in Ethiopia. AIDS Behav 2018;22:3815–25. 10.1007/s10461-018-2059-8
    1. van Hout B, Janssen MF, Feng Y-S, et al. . Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15. 10.1016/j.jval.2012.02.008
    1. Holzemer WL, Uys LR, Chirwa ML, et al. . Validation of the HIV/AIDS stigma instrument - PLWA (HASI-P). AIDS Care 2007;19:1002–12. 10.1080/09540120701245999
    1. Mesic A, Fontaine J, Aye T, et al. . Implications of differentiated care for successful ART scale-up in a concentrated HIV epidemic in Yangon, Myanmar. J Int AIDS Soc 2017;20:21644. 10.7448/IAS.20.5.21644
    1. Roberts DA, Tan N, Limaye N, et al. . Cost of differentiated HIV antiretroviral therapy delivery strategies in sub-Saharan Africa: a systematic review. J Acquir Immune Defic Syndr 2019;82:S339–47. 10.1097/QAI.0000000000002195

Source: PubMed

3
Prenumerera